Immune-endothelial-nerve interaction: An explanation for the failure of the gastrointestinal system in systemic sclerosis?

Annals of the Rheumatic Diseases

Volumn 68, Issue 5, 2009, Pages 609-610

  Matucci Cerinic, Marco ^a,c   Czirják, László ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PÉCS   (Hungary)

^c AOUC   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR; RECEPTOR ANTIBODY; MUSCARINIC M3 RECEPTOR;

ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; EDITORIAL; ENDOTHELIUM; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRACT; IMMUNE SYSTEM; MOLECULAR INTERACTION; NERVOUS SYSTEM; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; AUTOIMMUNE DISEASE; AUTONOMIC NERVOUS SYSTEM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; IMMUNOLOGY; NOTE; PATHOPHYSIOLOGY;

AUTOIMMUNE DISEASES; AUTONOMIC NERVOUS SYSTEM; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; RECEPTOR, MUSCARINIC M3; SCLERODERMA, SYSTEMIC;

EID: 66149131133     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.100479     Document Type: Editorial

References (21)

1. Kawaguchi Y, Nakamura Y, Matsumoto I, Nishimagi E, Satoh T, Kuwana M, et al. Muscarinic-3 acethylcholine receptor autoantibodies in severe gastrointestinal tract dysmotility. Ann Rheum Dis 2009;68:710-714
2. Dawson LJ, Allison HE, Stanbury J, Fitzgerald D, Smith PM. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 2004;43:1488-1495 (Pubitemid 39642571)
3. Schegg V, Vogel M, Didichenko S, Stadler MB, Beleznay Z, Gadola S, et al. Evidence that antimuscarinic antibodies in Sjögren's syndrome recognise both M3R and M1R. Biologicals 2008;36:213-222
4. Kovács L, Marczinovits I, György A, Tóth GK, Dorgai L, Pál J, et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3 (213-228) in primary Sjogren's syndrome. Rheumatology (Oxford) 2005;44:1021-1025
5. Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 1994;94:761-770 (Pubitemid 24251009)
6. Eaker EY, Kudau JG, Verne GN, Ross SO, Sallustio JE. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 1999;133:551-556 (Pubitemid 29257217)
7. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265-1282 (Pubitemid 24320743)
8. Ibba-Manneschi L, Del Rosso A, Pacini S, Tani A, Bechi P, Matucci-Cerinic M. Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis. Ann Rheum Dis 2002;61:754-756
9. Manetti M, Neumann E, Milia AF, Tarner IH, Bechi P, Matucci Cerinic M, et al. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis. Arthritis Rheum 2007;56:3442-3447 (Pubitemid 47585440)
10. Manetti M, Neumann E, Müller A, Schmeiser T, Saar P, Milia AF, et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008;58:2866-2873
11. Cohen SR, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest 1972;51:2663-2668
12. DiMarino AJ, Carlson G, Myers A, Schumacher HR, Cohen S. Duodenal myoelectric activity in scleroderma: abnormal responses to mechanical and hormonal stimuli. N Engl J Med 1973;289:1220-1223
13. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461-1467
14. Fulp SR, Castell DO. Scleroderma esophagus. Dysphagia 1990;5:204-210
15. Greydanus MR, Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989;96:110-115 (Pubitemid 19046273)
16. Pignone A, Scaletti C, Matucci-Cerinic M, Vázquez-Abad D, Meroni PL, Del Papa N, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolocapillary impairment. Clin Exp Rheumatol 1998;16:527-532 (Pubitemid 28439433)
17. Baroni Svegliati S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory antibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-2676 (Pubitemid 43920840)
18. Fineschi S, Goffin L, Rezzonico R, Cozzi F, Dayer JM, Meroni PL, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008;58:3913-3923
19. Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006;18:579-581
20. Smith VP, Van Praet JT, Vandooren BR, Vander Cruyssen B, Naeyaert JM, Decumen S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. Published Online First: 22 December 2008. doi:10.1136/ard.2008.095463.
21. Smith AJ, Jackson MW, Wang F, Cavill D, Rischmueller M, Gordon TP. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjögren syndrome. Hum Immunol 2005;66:411-416 (Pubitemid 40615797)